Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMpower110: Atezolizumab vs Chemotherapy in PD-L1+ NSCLC
NCT02409342Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2015
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Jul 2015; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02409342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02409342.